Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Sarah Phat"'
Autor:
Louisa Dowal, Pooja Parameswaran, Sarah Phat, Syamala Akella, Ishita Deb Majumdar, Jyoti Ranjan, Chahan Shah, Saie Mogre, Kalyani Guntur, Khampaseuth Thapa, Stephane Gesta, Vivek K. Vishnudas, Niven R. Narain, Rangaprasad Sarangarajan
Publikováno v:
Mediators of Inflammation, Vol 2017 (2017)
Obesity is marked by chronic, low-grade inflammation. Here, we examined whether intrinsic differences between white and brown adipocytes influence the inflammatory status of macrophages. White and brown adipocytes were characterized by transcriptiona
Externí odkaz:
https://doaj.org/article/4440b470a131444c8abf9b4b553092fa
Autor:
Anna F. Farago, Roman K. Thomas, Nicholas Dyson, Martin Peifer, Daniel A. Haber, Shyamala Maheswaran, Mehmet Toner, Aaron N. Hata, Kwok-Kin Wong, Alice T. Shaw, Lecia V. Sequist, Stefan Haas, Reinhard Büttner, Rebecca S. Heist, Sotirios Lakis, Roopika Menon, Nima Abedpour, Roxana Azimi, Kandarp N. Jani, Marina Kem, Maria Gomez-Caraballo, Joseph A. Licausi, Mehlika H. Hazar-Rethinam, Peter Igo, Jun Zhong, David T. Myers, Sarah Phat, Tilak Sundaresan, Ruben Dries, Mari Mino-Kenudson, Camilla L. Christensen, Julie George, Benjamin J. Drapkin
Supplementary Tables S3-S8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34f810bd30d67fc9f15933df0348ce6c
https://doi.org/10.1158/2159-8290.22532980
https://doi.org/10.1158/2159-8290.22532980
Autor:
Benjamin J. Drapkin, Nicholas J. Dyson, Mari Mino-Kenudson, Alice T. Shaw, Michael S. Lawrence, Daniel A. Haber, Shyamala Maheswaran, Aaron N. Hata, Lecia V. Sequist, Subba R. Digumarthy, Elizabeth A. Kennedy, Taronish D. Dubash, Marina Kem, Robert Morris, David T. Myers, Sarah Phat, David A. Barbie, Deepa Rangachari, Jun Zhong, J. Paul Marcoux, Rebecca S. Heist, Yin P. Hung, Marcello Stanzione, Beow Y. Yeap, Anna F. Farago
Clinical trial protocol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::603038b2af1af43459cbf1c89b06a323
https://doi.org/10.1158/2159-8290.22536920.v1
https://doi.org/10.1158/2159-8290.22536920.v1
Autor:
Anna F. Farago, Roman K. Thomas, Nicholas Dyson, Martin Peifer, Daniel A. Haber, Shyamala Maheswaran, Mehmet Toner, Aaron N. Hata, Kwok-Kin Wong, Alice T. Shaw, Lecia V. Sequist, Stefan Haas, Reinhard Büttner, Rebecca S. Heist, Sotirios Lakis, Roopika Menon, Nima Abedpour, Roxana Azimi, Kandarp N. Jani, Marina Kem, Maria Gomez-Caraballo, Joseph A. Licausi, Mehlika H. Hazar-Rethinam, Peter Igo, Jun Zhong, David T. Myers, Sarah Phat, Tilak Sundaresan, Ruben Dries, Mari Mino-Kenudson, Camilla L. Christensen, Julie George, Benjamin J. Drapkin
Supplementary Figures 1-11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b46abd95e690e774e3948ecc8c7622db
https://doi.org/10.1158/2159-8290.22532986
https://doi.org/10.1158/2159-8290.22532986
Autor:
Benjamin J. Drapkin, Nicholas J. Dyson, Mari Mino-Kenudson, Alice T. Shaw, Michael S. Lawrence, Daniel A. Haber, Shyamala Maheswaran, Aaron N. Hata, Lecia V. Sequist, Subba R. Digumarthy, Elizabeth A. Kennedy, Taronish D. Dubash, Marina Kem, Robert Morris, David T. Myers, Sarah Phat, David A. Barbie, Deepa Rangachari, Jun Zhong, J. Paul Marcoux, Rebecca S. Heist, Yin P. Hung, Marcello Stanzione, Beow Y. Yeap, Anna F. Farago
Small-cell lung cancer (SCLC) is an aggressive malignancy in which inhibitors of PARP have modest single-agent activity. We performed a phase I/II trial of combination olaparib tablets and temozolomide (OT) in patients with previously treated SCLC. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::869258f3af20f270daabeb7a145a2298
https://doi.org/10.1158/2159-8290.c.6548270.v1
https://doi.org/10.1158/2159-8290.c.6548270.v1
Autor:
Anna F. Farago, Roman K. Thomas, Nicholas Dyson, Martin Peifer, Daniel A. Haber, Shyamala Maheswaran, Mehmet Toner, Aaron N. Hata, Kwok-Kin Wong, Alice T. Shaw, Lecia V. Sequist, Stefan Haas, Reinhard Büttner, Rebecca S. Heist, Sotirios Lakis, Roopika Menon, Nima Abedpour, Roxana Azimi, Kandarp N. Jani, Marina Kem, Maria Gomez-Caraballo, Joseph A. Licausi, Mehlika H. Hazar-Rethinam, Peter Igo, Jun Zhong, David T. Myers, Sarah Phat, Tilak Sundaresan, Ruben Dries, Mari Mino-Kenudson, Camilla L. Christensen, Julie George, Benjamin J. Drapkin
Text for supplement: Supplementary methods, supplementary figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::586489d43da5a02a685492078b08e5d8
https://doi.org/10.1158/2159-8290.22532977.v1
https://doi.org/10.1158/2159-8290.22532977.v1
Autor:
Benjamin J. Drapkin, Nicholas J. Dyson, Mari Mino-Kenudson, Alice T. Shaw, Michael S. Lawrence, Daniel A. Haber, Shyamala Maheswaran, Aaron N. Hata, Lecia V. Sequist, Subba R. Digumarthy, Elizabeth A. Kennedy, Taronish D. Dubash, Marina Kem, Robert Morris, David T. Myers, Sarah Phat, David A. Barbie, Deepa Rangachari, Jun Zhong, J. Paul Marcoux, Rebecca S. Heist, Yin P. Hung, Marcello Stanzione, Beow Y. Yeap, Anna F. Farago
Supplementary Tables and Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2877541e2ac7d79c3dd29760a9114d7a
https://doi.org/10.1158/2159-8290.22536917.v1
https://doi.org/10.1158/2159-8290.22536917.v1
Autor:
Benjamin J. Drapkin, Nicholas J. Dyson, Mari Mino-Kenudson, Alice T. Shaw, Michael S. Lawrence, Daniel A. Haber, Shyamala Maheswaran, Aaron N. Hata, Lecia V. Sequist, Subba R. Digumarthy, Elizabeth A. Kennedy, Taronish D. Dubash, Marina Kem, Robert Morris, David T. Myers, Sarah Phat, David A. Barbie, Deepa Rangachari, Jun Zhong, J. Paul Marcoux, Rebecca S. Heist, Yin P. Hung, Marcello Stanzione, Beow Y. Yeap, Anna F. Farago
Supplementary Tables 4-5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93e0d55f5d181ccc6a8c9fce9aced2ae
https://doi.org/10.1158/2159-8290.22536914
https://doi.org/10.1158/2159-8290.22536914
Autor:
Ryan B. Corcoran, Catriona B. Hong, Heather A. Shahzade, Edmond Wong, David T. Myers, Sarah Phat, Ferran Fece de la Cruz, Meagan B. Ryan
Supplementary Figure S9. Combined SHP2 and KRASG12C inhibition improves efficacy in vivo.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36e0ce62dc6842a3a9f85242ad681822
https://doi.org/10.1158/1078-0432.22478093
https://doi.org/10.1158/1078-0432.22478093
Autor:
Ryan B. Corcoran, Catriona B. Hong, Heather A. Shahzade, Edmond Wong, David T. Myers, Sarah Phat, Ferran Fece de la Cruz, Meagan B. Ryan
Purpose:Although KRAS represents the most commonly mutated oncogene, it has long been considered an “undruggable” target. Novel covalent inhibitors selective for the KRASG12C mutation offer the unprecedented opportunity to target KRAS directly. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bd99c24a4188efa3cd8bb5f973c75ef
https://doi.org/10.1158/1078-0432.c.6529850
https://doi.org/10.1158/1078-0432.c.6529850